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Abstract
The effect of TNF-blockers on T-lymphocyte subsets is largely unknown in inflammatory bowel diseases (IBDs). The aim 
of the present study was to analyze the prevalence of T-cell subtypes and their correlation to therapeutic response. Sixty-
eight patients with Crohn’s disease (CD), 46 with ulcerative colitis (UC) were enrolled. (1) The clinical course was followed 
after the initiation of TNF-blockers (prospective study). (2) The immunophenotype was also compared between long-term 
anti-TNF treated-responders and non-responders (cross-sectional study). The results were compared with those of therapy-
naïve patients with active disease and those in remission with non-biological immunosuppressive therapy, and with healthy 
controls. Fourteen subtypes of peripheral blood T cells were measured with flow cytometry. The prevalence of Th2 and Th17 
cells, of HLA-DR- and CD69-positive CD4 and CD8 cells, was higher, whereas the percentage of CD45RA-positive CD4 
and CD8 cells was lower in both IBDs than in controls. CD8CD69 cell frequency was lower in remission, and decreased 
during anti-TNF therapy in CD responders. CD8CD45RO memory cells had higher prevalence in UC non-responders than 
in those starting anti-TNF. CD4CD45RO percentage < 49.05 at the initiation of TNF-blockers was predictive of a subsequent 
therapeutic response in CD, and Th2 and Th17 prevalence correlated with the duration of remission on TNF-blockers in 
UC. This study provided a detailed description of the T-cell composition in IBDs. CD8CD69 prevalence may be an activity 
marker in CD, and CD4CD45RO, Th2 and Th17 levels could be predictive for a therapeutic response to anti-TNF.
Keywords Th17 · Memory T cell · Therapeutic response
Introduction
Inflammatory bowel diseases (IBDs) are chronic immune-
mediated diseases involving the gastrointestinal tract and are 
frequently associated with extra-intestinal manifestations. 
IBDs comprise two well-characterized diseases, Crohn’s dis-
ease (CD) and ulcerative colitis (UC). The pathogenesis of 
IBD is still not clearly understood despite intensive research, 
but an inappropriate mucosal immune response to gut micro-
flora is a well-recognized phenomenon in the pathogenesis 
(Ogura et al. 2001; Lamas et al. 2016). Both the innate and 
the adaptive immune system play important roles in the 
intestinal inflammation. T-lymphocytes comprise a complex 
collection of highly differentiated T-cell subsets playing key 
roles in the regulation and the effector phase of the immune 
response. T-cell phenotype changes have been described 
in IBD models (Franchi et al. 2017; Zimmermann et al. 
2016) and also in human studies (Eastaff-Leung et al. 2010; 
Mayne and Williams 2013; Yamada et al. 2016; Zhang et al. 
2006; Sarra et al. 2010). Decreased numbers of regulatory 
T cells (Treg) were observed in the circulation and also in 
the inflamed mucosa (Eastaff-Leung et al. 2010; Mayne and 
Williams 2013; Yamada et al. 2016), and the importance 
of Th17 cells is definite as well (Zhang et al. 2006; Sarra 
et al. 2010). There is an established difference between the 
two major representative IBD subgroups as CD is associated 
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with Th1 (Fuss et al. 1996), whereas UC is more likely 
linked with a Th2 predominant profile (Pastorelli et al. 2010; 
Seidelin et al. 2010, 2015; Tanaka et al. 2010), although this 
dichotomy is not universal (Wallace et al. 2014).
Biological therapies targeting tumor necrosis factor-α 
(anti-TNF) are highly effective hallmark therapies in IBD. 
Despite their widespread use, the impact of TNF-blocking 
agents on the composition of the adaptive immune system 
is largely unexplored. In our two previous studies in rheu-
matoid arthritis (RA) and ankylosing spondylitis (AS), in 
which anti-TNF therapies are also highly beneficial, we 
found significant differences in the T-cell subset composi-
tion among responder and non-responder patients (Dulic 
et al. 2017, 2018). Key findings were the normalization of 
Treg frequencies and the phenotypic pattern of a continuing 
T-cell activation, as reflected by several activation mark-
ers. The prevalence of CD4CD69 cells at the initiation of 
anti-TNF therapy appeared as a predictive biomarker of a 
subsequent therapeutic response in RA. Knowledge on such 
effects in IBDs could clarify the mechanism of action of 
these therapies in CD and UC, provide information about 
the status of the adaptive immune system, and could help 
finding cell-based markers.
Patients and Methods
To obtain a deeper insight into the changes in the composi-
tion of the adaptive immune system during anti-TNF therapy 
in IBD, and to seek for clinically relevant conclusions, we 
have separated our study design to two approaches: the first 
one was a prospective follow-up of CD and UC patients, in 
whom anti-TNF therapy was initiated. The second one was 
a cross-sectional comparison of the immune phenotype of 
IBD patients on established anti-TNF therapy, grouped as 
anti-TNF-responders and non-responders; these data were 
compared with results from active, therapy-naïve and inac-
tive (treated) IBD patients. Altogether 114 patients were 
enrolled. We have measured the prevalence of 14 types of 
T-cell subsets.
Patients
CD and UC patients (n = 16 for each disease) were enrolled, 
in whom the disease was active despite therapy with non-
biologic immunosuppressive therapies, and in whom anti-
TNF therapy was initiated after blood sampling (abbreviated 
as CDstart or UC start group). All patients had a Crohn’s 
Disease Activity Index (CDAI) (Best et al. 1976) > 220 
(Colombel et al. 2009), or Mayo score > 6 (Schroeder et al. 
1987). Patients were classified to disease subsets following 
the Montreal classification criteria (Satsangi et al. 2006).
During subsequent follow-up, treatment was con-
ducted following the current international guidelines 
and the best clinical judgement of the treating physician, 
and data on the subsequent disease activity and therapy 
were recorded. Short-term (3  months) and long-term 
(12 months) response to anti-TNF therapy was assessed. 
Response was defined as a reduction of > 50% in CDAI, 
or, for UC patients, in the Mayo score, or when endoscopy 
was not performed at the time of assessment, in the partial 
Mayo (pMayo) score (Lewis et al. 2008; Sands et al. 2004) 
without an increase in the anti-TNF dose above standard 
dose. Non-response (primary or relapse) was established 
if these activity index-based criteria were not fulfilled, 
or based on the clinical assessment of the treating physi-
cian, corticosteroid had to be introduced, or its dose had 
to be increased, or anti-TNF dose had to be increased over 
standard dose, or surgical intervention for active IBD has 
become necessary, or anti-TNF therapy had to be switched 
to either another anti-TNF or to a biological of different 
class. The length of the response period was also recorded. 
For reimbursement requirements, in some patients at sta-
ble remission after 12 months of anti-TNF therapy, the 
drug was discontinued, and only non-biological mainte-
nance therapy was continued. Disease course after such 
forced therapy withdrawal was also followed-up. In six 
patients from each disease group, control blood sampling 
was performed after at least 3 months of anti-TNF therapy, 
and the same laboratory examinations were repeated.
As a further assessment, patients on established 
(> 3  month duration) anti-TNF therapy were also 
involved. Thirty-one patients with CD and 16 with UC 
were included, and were distinguished as responders 
(CDresporUCresp) or non-responders (CDnonrespor 
UCnonresp) to anti-TNF therapy as defined following 
the response criteria described in the previous paragraph. 
Their laboratory results were compared with each other, 
and with those of the members of CDstart or UCstart 
groups. The six patients in either the CDstart or UCstart 
groups, in whom repeated laboratory examinations were 
performed during anti-TNF treatment, were also involved 
in the responder or non-responder groups for comparison 
with the anti-TNF starter groups.
As controls, the following groups were formed and ana-
lyzed: (1) patients with newly diagnosed, active, untreated 
CD or UC: CDnew (n = 7), UCnew (n = 7); (2) patients 
with inactive disease controlled with non-biologic immu-
nosuppressive drugs: CDinact (n = 14), UCinact (n = 7), 
and (3) age- and sex-matched healthy controls (n = 30). 
All participants gave their informed consent, and the 
study was conducted in concert with the principles of the 
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Helsinki declaration (ethical approval: ETT-TUKEB 905/
PI/09).
Laboratory Measurements
Fifteen ml of anticoagulated blood samples were taken, and 
peripheral blood mononuclear cells (PBMCs) were sepa-
rated by centrifugation with Ficoll-Paque (GE Healthcare 
Life Sciences, Pittsburgh, PA, USA). Full blood counts 
revealed that white blood cell and lymphocyte numbers 
were within normal limits (4–12 G/L and 1–4 G/L, respec-
tively) for all participants. PBMCs were frozen and kept 
at − 80  °C until analysis. After thawing, samples were 
washed twice with phosphate-buffered saline solution 
(pH 7.4). CD3+ T cells were enriched using the EasySep 
Human T Cell Enrichment Kit (Stemcell Technologies, 
Cambridge, MA, USA). The following fluorescent antibod-
ies (Becton-Dickinson, San Diego, CA, USA) were applied 
for cell surface staining: CD4 PE-Cy7 (clone SK3), CD8 
APC-Cy7 (clone SK1), CXCR3 APC (clone 1C6/CXCR3), 
CCR4 PE (clone 1G1), CCR6 PerCP-Cy5.5 (clone 11A9), 
CD25 FITC (clone M-A251), CD69 APC (clone FN50), 
HLA-DR PerCP-Cy5.5 (clone G46-6), CD45RA FITC 
(clone HI100), CD45RO PE (clone UCHL1). T-cell sub-
types were differentiated using the following gating strat-
egy (Fig. 1): helper T cells (CD4+CD8−), cytotoxic T 
cells (CD4−CD8+), Th1 cells (CD4+CXCR3+CCR4−), 
Th2 cells (CD4+CXCR3−CCR4+), Th17 cells 
(CD4+CCR4+CCR6+), Tregs (CD4+CD25 high). The 
proportion of cells expressing the early (CD69), or the 
late (HLA-DR) activation markers as well as naive T cells 
(CD45RA+CD45RO−) and memory T cells (CD45RA-
CD45RO+) were also determined within both the CD4+ and 
CD8+ subsets. An average of 200,000 cells was registered 
for each acquisition. All measurements were performed on a 
BD FACSAria flow cytometer (BectonDickinson, San Jose, 
CA, USA). Cell proportion values were determined with 
conventional gating, through the use of FACSDiva software 
(BectonDickinson, San Jose, CA, USA).
Statistical Methods
Clinical data are presented as mean (range), whereas cell 
subtype prevalence values as mean ± SD or median (25–75 
percentile) depending on the distribution of the values. 
Cell subset percentage values were compared among 
groups with two-sample t test or Mann–Whitney test if two 
groups were compared, or with analysis of variance or with 
Kruskal–Wallis test, with Bonferroni’s or Dunn’s tests for 
multiple comparisons, respectively, if more than two groups 
were analyzed. We have applied the ANOVA for the com-
parison of all the ten patient subgroups and healthy controls, 
and also for the comparison of selected UC or CD patient 
groups separately, to focus on clinically relevant questions. 
The patient subgroup analysis according to their therapeutic 
response or active vs inactive patient subgroups were per-
formed with Student test. Receiver-operated curve (ROC) 
analyses were performed to seek for values of baseline (i.e., 
the start of anti-TNF) cell percentages that would discrimi-
nate between patients in whom long-term remission was 
achieved in response to anti-TNF therapy, and Pearson’s 
correlation analysis was carried out to assess the correla-
tion between cell frequency values at the start of anti-TNF 
and the length of a subsequent remission. A p value < 0.05 
was taken statistically significant.
Results
Clinical Characteristics and Follow‑Up
The demographic and most important clinical data of the 
patients in all subgroups are summarized in Table 1. Patient 
subgroups for both diagnoses were similar in terms of age, 
disease duration, frequency of extraintestinal manifestations, 
surgical interventions necessitated by IBD, type of anti-TNF, 
other therapies ever used, or smoking status. Although there 
were numerical differences among the groups in terms of 
gender distribution, these were not statistically significant. 
However, CDinact patients less frequently had perianal man-
ifestations than anti-TNF-treated CD patients (both respond-
ers and non-responders), and anti-TNF therapy duration was 
shorter in UCnonresp patients than in UCresp patients.
The mean follow-up time of the patients after the 
blood sampling and the initiation of anti-TNF therapy was 
35 months for CD, and 24 months for UC patients. Follow-
up data are summarized in Table 2. Long-term therapeutic 
response to anti-TNF was observed in 14 of 16 CD patients 
and 9 of 16 UC patients. Primary non-response occurred 
slightly more often than loss of effect—secondary inef-
ficacy—in anti-TNF-refractory UC patients. The disease 
relapsed within 12 months in 9 of the 11 patients in whom 
anti-TNF was stopped after 1 year of successful therapy, and 
in only 2 of them was a biologic-free remission observed, 
during a follow-up period of 12 and 36 months, respectively.
Lymphocyte Subset Distribution
We have revealed a number of significant differences 
between healthy controls and IBD patients with respect of 
the prevalences of several T-cell subsets. Every CD or UC 
subgroup had higher frequencies of Th2 and Th17 cells 
(Fig. 2) than healthy controls. Although the proportion 
of CD4 cells was comparable across all groups, patients 
in all IBD subgroups had less naive (CD45RA+) T cells 
than healthy controls, whereas the proportion of activated 
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(CD69+ and HLA-DR+) T cells was higher in most IBD 
subgroups, especially in CD patients, than in healthy con-
trols (Fig. 3). In the CD8 compartment, similar conclu-
sions can be drawn, with the addition that the prevalence 
of memory T cells (CD45RO+) proved to be statistically 
significantly higher in 2 CD and 1 UC subgroup too (Fig. 4).
However, in contrast with our previous studies on RA 
and AS patients, relatively few differences could be dem-
onstrated between newly diagnosed cases and patients in 
remission, and among patients before and after the initiation 
of anti-TNF therapy. Significant differences among the vari-
ous patient subgroups based on their therapeutic response in 
the cross-sectional part are summarized in Fig. 5, and are as 
follows: CD4 proportion was lower in anti-TNF responder 
UC patients than in non-responders (31 ± 4.3 vs 50 ± 7.4, 
p < 0.05); however, there was no significant difference 
between CDresp and CDnonresp groups. CD8CD69 acti-
vated T cells were observed more frequently in newly diag-
nosed CD patients than in those whose disease has become 
inactive with conventional immunosuppressive therapy 
Fig. 1  Gating strategy to identify the investigated T-cell subsets. FSC forward scatter characteristics, SSC side scatter characteristics, ly lympho-
cytes
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(21.15 ± 9.13 vs 6.39 ± 2.23, p < 0.05); and CD8 memory 
cell prevalence was higher in anti-TNF non-responder UC 
patients than in UC patients at the time of anti-TNF-initia-
tion (20.57 ± 5.73 vs 11.40 ± 1.49, p < 0.05), whereas this 
parameter did not change significantly in anti-TNF responder 
UC patients. In contrast with our previous findings in RA 
and AS, Treg prevalence was not affected by anti-TNF ther-
apy in either IBD.
Finally, we analyzed if any of the cell prevalence values 
had a predictive value for the efficacy of anti-TNF therapy. We 
performed ROC analyses in the CDstart and UCstart groups 
to search for frequency values that could discriminate between 
patients with and without long-term remission, and we carried 
Table 2  Disease outcome after the initiation of anti-TNF therapy in 
IBD patients
For 4 UC patients, follow-up was shorter than 12 months, long-term 
response was, therefore, evaluable in 20 patients. For the definition of 
short-term and long-term response, see Patients section
CD (n = 16) UC (n = 16)
Duration of follow-up (months) 35 (16–47) 24 (2–46)
Short-term response achieved 15 12
Long-term response achieved 14 9
Duration of response 27 (0–47) 19 (0–46)
Fig. 2  Comparison of the frequencies of the major T helper cell sub-
sets among the various patient groups and controls. CDnew new-
onset Crohn’s disease (CD) patients, CDinactive CD patients with 
inactive disease on immunosuppressive therapy, CDstart patients 
with active CD in whom anti-TNF therapy is initiated, CDresp anti-
TNF-responder CD patients, CDnonresp anti-TNF-nonresponder 
CD patients. Abbreviations are analogous for ulcerative colitis (UC) 
patients. Data are presented as median (horizontal line within boxes), 
25 and 75 percentile (horizontal borders of the boxes), and minimum 
and maximum (whiskers). Numbers on the vertical axis indicate % 
within CD4 cells. *p < 0.05 vs healthy controls with ANOVA and 
Bonferroni’s correction
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out correlation analysis between the cell percentages and the 
duration of remission. In CD patients, CD4CD45RO cell 
prevalence of < 49.05% has predicted the long-term remis-
sion with a sensitivity of 100%, and a specificity of 92.3%, 
area under the curve (AUC): 1.0 (p = 0.03). CD4HLADR cell 
frequencies showed a near-significant (p = 0.058) correlation 
with the duration of remission (Pearson’s r = 0.50). In UC 
patients, there was a trend to significance (p = 0.08) for a CD4 
prevalence value of < 29.95 (sensitivity 66.67%, specificity 
87.50%, AUC 0.85), and Th2 and Th17 cell prevalence values 
showed a significant positive correlation with the duration of 
response (p = 0.03, Pearson’s r 0.59, and p = 0.03, Pearson’s r 
0.61, respectively), and a tendency with regard to a positive 
correlation with CD8HLADR (p = 0.06, Pearson’s r 0.59).
Discussion
The present study has provided a detailed characterization 
of the adaptive immune system in CD and UC, in particu-
lar, the prevalence of several T-cell subtypes that have 
not been studied before. Elevated frequencies of memory 
and activated T cells and decreased proportion of naïve T 
cells have been revealed in both diseases. Th17 cells were 
found to be expanded as compared with controls in both 
IBDs as reported before (Zhang et al. 2006; Sarra et al. 
2010). The finding of elevated Th2 cell percentages in 
UC is also in line with the majority of published results 
(Pastorelli et al. 2010; Seidelin et al. 2010, 2015; Tanaka 
et al. 2010), but in contrast with the previously presumed 
predominance of Th1 over Th2 in CD, according to our 
findings, Th1 cells have the same ratios in both CD and 
UC as those in healthy controls. The universal role of the 
Th1 skewing of T-cell differentiation has been questioned 
by some investigators (Wallace et al. 2014; Niessner and 
Volk 1995; Rovedatti et al. 2009), and the lack of a con-
vincing benefit of monoclonal antibody treatment targeting 
interferon-γ in CD (Cui et al. 2013) can also argue against 
the importance of this pathway. Furthermore, differences 
in disease activity, disease stage and patient population 
from the published examinations may also explain these 
discrepancies.
Fig. 3  Comparison of the frequencies of CD4 cell subsets among 
the various patient groups and controls. CDnew new-onset Crohn’s 
disease (CD) patients, CDinactive CD patients with inactive disease 
on immunosuppressive therapy, CDstart patients with active CD in 
whom anti-TNF therapy is initiated, CDresp anti-TNF-responder CD 
patients, CDnonresp anti-TNF-nonresponder CD patients. Abbrevia-
tions are analogous for ulcerative colitis (UC) patients. Data are pre-
sented as median (horizontal line within boxes), 25 and 75 percen-
tile (horizontal borders of the boxes), and minimum and maximum 
(whiskers). Numbers on the vertical axis indicate % within CD4 cells. 
*p < 0.05 vs healthy controls with ANOVA and Bonferroni’s correc-
tion
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Fig. 4  Comparison of the frequencies of CD8 cell subsets among 
the various patient groups and controls. CDnew new-onset Crohn’s 
disease (CD) patients, CDinactive CD patients with inactive disease 
on immunosuppressive therapy, CDstart patients with active CD in 
whom anti-TNF therapy is initiated, CDresp anti-TNF-responder CD 
patients, CDnonresp anti-TNF-nonresponder CD patients. Abbrevia-
tions are analogous for ulcerative colitis (UC) patients. Data are pre-
sented as median (horizontal line within boxes), 25 and 75 percen-
tile (horizontal borders of the boxes), and minimum and maximum 
(whiskers). Numbers on the vertical axis indicate % within CD4 cells. 
*p < 0.05 vs healthy controls with ANOVA and Bonferroni’s correc-
tion
Fig. 5  Statistically significant differences between particular patient 
subgroups. CDnew new-onset Crohn’s disease (CD) patients, CDi-
nactive CD patients with inactive disease on immunosuppressive 
therapy, CDstart patients with active CD in whom anti-TNF therapy 
is initiated, CDresp anti-TNF-responder CD patients, CDnonresp 
anti-TNF-nonresponder CD patients. Abbreviations are analogous for 
ulcerative colitis (UC) patients. Data are presented as median (hori-
zontal line within boxes), 25 and 75 percentile (horizontal borders of 
the boxes), and minimum and maximum (whiskers). Numbers on the 
vertical axis indicate % within CD4 cells. *p < 0.05 with Student t test
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The most remarkable finding is that CD8CD69-positive 
T-cell prevalence is an activity biomarker, because it is more 
abundant in active CD patients than in those in remission. 
Therefore, low CD8CD69 prevalence may confirm that the 
disease is in remission. This is in line with earlier literature 
highlighting the importance of CD69 in inflammatory bowel 
disease (Radulovic and Niess 2015). Of note, in some of 
our patients, the prevalence of circulating CD69+ cells was 
higher than expected, as these cells normally reside in the 
mucosa, interacting with the microbiome. Their egression 
into the periphery may indicate the importance of other cir-
culating antigens in the pathogenesis of IBD. Furthermore, 
spondylarthropathic disorders, including psoriatic arthritis 
have also been recently characterized by an increased fre-
quency of circulating CD8+ CD69+ T cells compared to 
psoriasis and healthy controls (Diani et al. 2019).
Lower than 49.05% prevalence of CD4CD45RO is a 
further putative biomarker, as it is predictive for long-term 
treatment response, but only in CD. A higher percentage 
of CD4HLADR in CD, and a higher frequency of Th2 and 
Th17 cells in UC can also predict a longer duration of remis-
sion. The importance of Th17 prevalence is also confirmed 
by the studies of Hull et al., who found that Th17 cell fre-
quency increases during anti-TNF therapy in RA, AS and 
psoriatic arthritis, and the increase is associated with the 
improvement of synovitis in RA (Hull et al. 2015, 2016).
Another goal of this examination was the analysis of 
changes in the circulating T-cell composition during anti-
TNF therapy. In contrast with our similar studies on RA and 
AS patients, we have found very little changes in the T-cell 
subset distribution when anti-TNF-treated and treatment-
naïve patients were compared, and the T-cell profile did 
not differ markedly between anti-TNF-responders and non-
responders. Our primary hypothesis for this finding is that 
in IBDs the most relevant immunological events happen in 
the gut mucosa-associated immune system, and are reflected 
less in the circulating lymphocyte pool than in RA and AS. 
We propose, therefore, that studies on the pharmacodynamic 
immunological effects of anti-TNF, and possibly other novel 
targeted therapies are more appropriate from mucosal biop-
sies than from peripheral blood, or parallel samplings from 
endoscopic biopsies and peripheral blood should be per-
formed. We note that peripheral blood T-cell composition 
did prove to be useful for the description of the adaptive 
immune system when CD and UC patients were compared 
with healthy individuals, and it may be possible that an even 
longer follow-up would be needed until the putative mucosal 
immune alterations would proceed to the systemic immune 
system.
In summary, several candidate cell-based biomarkers 
have emerged: CD8CD69 in both IBDs, CD4CD45RO and 
CD4HLADR in CD, and CD4, Th2, Th17 and CD8HLADR 
in UC all seem to be promising markers of remission or of 
the prediction of a therapeutic response to anti-TNF. Since 
only 40–50% of patients achieve a good and sustained reac-
tion to anti-TNF treatment (Bálint et al. 2016), and the cause 
of the failure was primary non-response in most of our cases, 
validation of these finding would provide us with tools for 
a more personalized choice from the growing number of 
classes of targeted therapies in IBD.
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